Peptides — short chains of amino acids (2–50 residues) serving as signaling molecules that regulate protein synthesis, enzyme activity, cell communication, and structural support — have become one of skincare's largest growth categories. Their conceptual appeal is logical: collagen is built from peptides, so applying peptides should support collagen synthesis. The reality is more nuanced: peptide absorption through intact stratum corneum is poor for most sequences (the skin barrier's primary function is to keep things out), different peptide classes work through fundamentally different mechanisms, and the evidence quality for specific ingredients varies dramatically from well-designed clinical trials to marketing claims with no published supporting data.
Signal Peptides: Palmitoyl Pentapeptide (Matrixyl)
Signal peptides trigger cellular responses by mimicking endogenous signaling sequences — often fragments of extracellular matrix proteins that signal tissue damage and stimulate repair. Palmitoyl pentapeptide-4 (Matrixyl, Sederma) — a palmitoyl-linked fragment of procollagen type I — is the best-evidenced topical peptide for anti-aging. A 2005 double-blind RCT published in the International Journal of Cosmetic Science found 3% Matrixyl significantly reduced wrinkle volume, area, and depth compared to placebo after 56 days. Matrixyl 3000 (a Matrixyl + palmitoyl tetrapeptide-7 combination) increased procollagen synthesis 2.1× and fibronectin 1.6× versus control in ex vivo skin models. While clinical studies are predominantly conducted or funded by Sederma (the manufacturer), the mechanistic plausibility and consistent trial results provide reasonable evidence for this ingredient class.
Neurotransmitter Inhibitor Peptides: Argireline
Acetyl hexapeptide-3 (Argireline, Lipotec) is marketed as a "topical Botox" — inhibiting SNAP-23 neurotransmitter release at the neuromuscular junction, theoretically reducing muscle contraction-driven dynamic wrinkles. In vitro studies confirm argireline inhibits catecholamine release; in vivo studies show modest wrinkle reduction with 10% argireline versus vehicle. The clinical effect magnitude is significantly smaller than botulinum toxin injection (the mechanism requires penetration to the neuromuscular junction, which is far below where topical products typically reach) — making the "topical Botox" comparison misleading, though modest wrinkle reduction effects appear real at high concentrations. Most formulated products contain 2–5% argireline, below the 10% used in positive clinical trials.
Copper Peptides: GHK-Cu
Glycine-histidine-lysine-copper (GHK-Cu) — originally isolated from human plasma as a wound-healing stimulating factor — has demonstrated wound healing, anti-inflammatory, and collagen/glycosaminoglycan stimulating effects in multiple in vitro and animal studies. Human clinical trials for cosmetic applications are limited but include a 2001 Aesthetic Plastic Surgery study showing skin tightening and wrinkle reduction equivalent to vitamin C at 3% GHK-Cu. GHK-Cu also has FDA-orphan-drug designation for chronic wound healing applications — one of the few cosmetic peptides with dual cosmetic/pharmaceutical development tracks. The copper component raises questions about toxicological accumulation with long-term use at high concentrations — standard cosmetic concentrations of 0.5–3% are considered safe based on published toxicology. Healthcare providers can find wound care and skin support products through our skin care and wound care catalogs.
